| Small agents |
Not available |
Deferoxamine (DFO) |
Imine |
Murine model of acute iron toxicity |
Prevent the mortality |
57
|
| HES 130/0.4 |
Methotrexate (MTX) |
Ester |
P388 murine leukaemia, MV-4-11 human leukaemia |
Higher antitumor efficacy |
58
|
| HES 130/0.4 |
Doxorubicin (DOX) |
Imine |
B16F10 melanoma |
Acid-sensitive, enhanced antitumor activity and security |
61
|
| HES 130/0.4 |
Doxorubicin (DOX) |
Imine |
A375 human malignant melanoma |
Targeted acid-sensitive and improved antitumor efficacy |
62
|
| HES 130/0.4 |
Doxorubicin (DOX) |
Hydrazone |
No |
Acid responsiveness, better proliferation inhibition in HepG2 cells |
63
|
| HES 130/0.4 |
Doxorubicin (DOX) |
Imine |
RM-1-xenografted C57BL/6 mouse |
pH-responsive, improved distribution, anti-tumor and anti-metastasis |
64
|
| HES 200/0.5 |
Doxorubicin (DOX) |
Amide |
H22-tumor mice model |
Redox-sensitive, targeted drug delivery and better antitumor efficacy |
65
|
| HES 130/0.4 |
5-Fluorouracil (5-Fu) |
Ester |
SD rats |
Sustained-release of FUAC |
66
|
| HES 200/0.5 |
Curcumin (CUR) |
Ester |
No |
Improved solubility and stability of CUR, better anticancer activity |
67
|
| HES 200/0.5 |
cis-Platinum (Pt) |
Ester |
No |
Improved solubility of Pt, targeted delivery to HepG-2 cancer cells |
28
|
| HES 200/0.5, HES 130/0.4 |
10-Hydroxy camptothecin (10-HCPT) |
Amide |
Hep-3B solid tumor in nude mice |
Improved solubility and stability of 10-HCPT, higher cytotoxicity |
70 and 71
|
| HES 130/0.4 |
Paclitaxel (PTX) |
Disulfide bond |
4T1-tumor mice model |
α-Amylase- and redox-responsive, increased in vivo half life time |
73
|
| Biomolecules |
HES 130/0.5 |
Erythropoietin (AGEM400) |
Thioether |
No |
Prolonged half-life, superior efficacy |
77
|
| HES 85 kDa |
Anakinra |
Imine |
Male Wistar rats |
Extended half-life |
78
|
